Compare VTEX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | XNCR |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.7M | 881.9M |
| IPO Year | 2019 | 2013 |
| Metric | VTEX | XNCR |
|---|---|---|
| Price | $3.92 | $11.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $5.97 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.0M | 689.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $9.63 | $4.80 |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $2.84 | $6.92 |
| 52 Week High | $6.82 | $18.69 |
| Indicator | VTEX | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 42.58 |
| Support Level | $3.92 | $10.93 |
| Resistance Level | $4.21 | $12.87 |
| Average True Range (ATR) | 0.18 | 0.69 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 16.15 | 6.12 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.